Mirum Pharmaceuticals, Inc. - 8-K Filing
Mirum's Phase 3 EXPAND study of LIVMARLI met primary endpoint and all secondary endpoints in treating cholestatic pruritus. (Items: 8.01 Other Events)
7 articles from 1 source · updated
Coverage
- Disc Medicine, Inc. - 8-K Filing SEC EDGAR ·
- ELITE PHARMACEUTICALS INC /NV/ - 4 Filing SEC EDGAR ·
- ADIAL PHARMACEUTICALS, INC. - 8-K Filing SEC EDGAR ·
- NRX Pharmaceuticals, Inc. - 8-K Filing SEC EDGAR ·
- Apimeds Pharmaceuticals US, Inc. - 8-K Filing SEC EDGAR ·
- Phio Pharmaceuticals Corp. - 8-K Filing SEC EDGAR ·
- Mirum Pharmaceuticals, Inc. - 8-K Filing SEC EDGAR ·